The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Analysis Group
Consulting or Advisory Role - AstraZeneca (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Expert Testimony - Abbvie
Factors associated with receipt and overall survival of concurrent chemoradiotherapy versus single modality therapy in unresectable stage III NSCLC.
 
Jorge E. Gomez
Employment - Mount Sinai Hospital
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Mount Sinai Hospital
Research Funding - AstraZeneca
 
Kellie Ryan
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Priyanka J. Bobbili
Employment - Analysis Group
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Akanksha Dua
Employment - Analysis Group
Consulting or Advisory Role - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Novartis (Inst); Teva (Inst)
 
Maral DerSarkissian
Employment - Analysis Group
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Novartis (Inst); Novo Nordisk (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Takeda (Inst)
 
Mei Sheng Duh
No Relationships to Disclose